Toronto Research Chemicals

 

Toronto Research Chemicals, TRC was founded in 1982 to manufacture and supply researchers in the biomedical fields with specialized complex organic small molecules not otherwise commercially available. Today, Toronto Research Chemicals Inc. employs more than 300 full time staff, of which approximately 200 are PhD's and MSc's, operating in 120,000 square feet of facilities, including 15 production laboratories, in Toronto, Canada. 

 

TRC currently offers an extensive catalogue in excess of 200,000 products with an extensive inventory for immediate shipment. Where stock is unavailable, TRC will undertake production of new and known compounds upon customer order. Toronto Research Chemicals supports the global scientific community across more than 105 countries.

 
 Learn more :
 

  

 

 

 

   
           

       

               

Brochure

 

 

Cancer Research

 

     

Infectious Disease Research

 

     

Neurodegenerative Diseases

and Mental Disorders

    

 

 

 

 
 
EGFR probe for ISH CE/IVD - Brain and neural pathology

EGFR probe for ISH CE/IVD - Brain and neural pathology

 

The receptor for epidermal growth factor (EGFR) also known as HER1 or ERBB1, is a transmembrane receptor tyrosine kinase of the ERBB family. This is a family of four receptors (ERBB1-4 or HER1-4) with EGFR the best characterized. EGFR is a prime target for cancer therapy across a broad variety of tumor types. Glioblastoma is the most common malignant brain tumor in adults, and among the most lethal of all cancers. Glioblastomas are divided into four subtypes: classical, proneural, mesenchymal and neural. EGFR amplification is enriched in the classical subtype. Amplification of the EGFR gene occurs in 57.4% of primary glioblastoma patients compared to 8% of secondary glioblastoma patients and is associated with high levels of EGFR protein. EGFR deletions in glioblastoma include EGFRvI (N-terminal deletion), vII (deletion of exons 14–15), vIII (deletion of exons 2–7), vIV (deletion of exons 25–27), vV (deletion of exons 25–28), among which vII and vIII are oncogenic.

 

 

Search result : 2 product found

Refine your search :

RUOCE / IVD
  • Inhibitor/Antagonist/Agonist 2
APPLY FILTERS
REINITIALIZE


Cat#
Description
Cond.
Price Bef. VAT
TRC-E244110-500MG
 500mg